Clarithromycin is inactive against Mycobacterium tuberculosis.

Antimicrobial Agents and Chemotherapy
C Truffot-PernotB Ji

Abstract

When 10% oleic acid-albumin-dextrose-catalase-enriched Mueller-Hinton agar medium was employed, the MICs of clarithromycin (CLARI) at which 50 and 90% of 12 strains of Mycobacterium tuberculosis were inhibited were 64 and > 128 micrograms/ml, respectively, which are significantly greater than the achievable peak CLARI concentrations in serum and in lung tissue in humans. In two different mouse experiments, 4 to 6 weeks of treatment with CLARI at 200 mg/kg of body weight six times weekly produced neither bactericidal nor bacteriostatic effects against M. tuberculosis. Therefore, we conclude that CLARI as a single drug is inactive against M. tuberculosis.

References

Jan 1, 1992·Diagnostic Microbiology and Infectious Disease·D J HardyR N Jones
Feb 1, 1991·The Journal of Antimicrobial Chemotherapy·F FraschiniG Demartini
Aug 1, 1991·Antimicrobial Agents and Chemotherapy·C Truffot-PernotJ Grosset
Nov 1, 1994·American Journal of Respiratory and Critical Care Medicine·L ChapuisJ H Grosset
Nov 1, 1993·Antimicrobial Agents and Chemotherapy·S P KlemensM H Cynamon
Sep 9, 1993·The New England Journal of Medicine·M D Iseman

❮ Previous
Next ❯

Citations

Dec 14, 2004·The Journal of Antimicrobial Chemotherapy·Kevin A NashRichard J Wallace
Jun 28, 2006·Antimicrobial Agents and Chemotherapy·Nadya Andini, Kevin A Nash
Dec 20, 2000·Antimicrobial Agents and Chemotherapy·B Vester, S Douthwaite
Oct 16, 2001·Antimicrobial Agents and Chemotherapy·N LounisJ Grosset
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·Karolína BuriánkováJean-Luc Pernodet
Feb 14, 2004·Lancet·Joia S MukherjeeKwonjune J Seung
Aug 15, 2003·American Journal of Respiratory and Critical Care Medicine·Roly D GoslingStephen H Gillespie
Dec 4, 2003·American Journal of Respiratory and Critical Care Medicine·Richard J O'Brien
Aug 13, 2004·American Journal of Respiratory and Critical Care Medicine·Eric L NuermbergerJacques H Grosset
Sep 10, 2005·American Journal of Respiratory and Critical Care Medicine·Eric NuermbergerJacques H Grosset
Jul 29, 2003·Expert Opinion on Investigational Drugs·Peter D O Davies, W W Yew
Jul 11, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·G Bothamley
Oct 10, 2008·Tuberculosis·Zhaohai J ZhuScott G Franzblau
May 20, 2008·Tuberculosis
Jul 19, 2012·The Journal of Infectious Diseases·Kelly E DooleyUNKNOWN Efficacy Subgroup, RESIST-TB
Mar 31, 2016·PloS One·Gregory J FoxUNKNOWN Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB
Jul 30, 2004·The Journal of Antimicrobial Chemotherapy·Giovanni Di Perri, Stefano Bonora
May 30, 2015·The European Respiratory Journal·Anne-Fleur van der PaardtJan-Willem C Alffenaar
Sep 22, 2005·The Journal of Biological Chemistry·Christian Toft MadsenStephen Douthwaite
Nov 16, 2019·American Journal of Respiratory and Critical Care Medicine·Payam NahidBarbara Seaworth
Nov 14, 2018·Antimicrobial Agents and Chemotherapy·Virginia MeikleMichael Niederweis

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.